Reno Debets

9.3k total citations · 1 hit paper
161 papers, 6.2k citations indexed

About

Reno Debets is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Reno Debets has authored 161 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Oncology, 96 papers in Immunology and 37 papers in Molecular Biology. Recurrent topics in Reno Debets's work include CAR-T cell therapy research (80 papers), Immunotherapy and Immune Responses (53 papers) and Cancer Immunotherapy and Biomarkers (50 papers). Reno Debets is often cited by papers focused on CAR-T cell therapy research (80 papers), Immunotherapy and Immune Responses (53 papers) and Cancer Immunotherapy and Biomarkers (50 papers). Reno Debets collaborates with scholars based in Netherlands, United Kingdom and Germany. Reno Debets's co-authors include C. B. H. W. Lamers, Stefan Sleijfer, Jan W. Gratama, Ralph A. Willemsen, Egbert Oosterwijk, Hinrich Abken, Coen Govers, Errol P. Prens, Arnold G. Vulto and C.A.M. van der Velden-de Groot and has published in prestigious journals such as Nature Medicine, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Reno Debets

151 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

2013 561 citations Stefan Sleijfer, Reno Debets et al. profile →

Peers

Countries citing papers authored by Reno Debets

Since Specialization

Citations

This map shows the geographic impact of Reno Debets's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reno Debets with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reno Debets more than expected).

Fields of papers citing papers by Reno Debets

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reno Debets. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reno Debets. The network helps show where Reno Debets may publish in the future.

Co-authorship network of co-authors of Reno Debets

This figure shows the co-authorship network connecting the top 25 collaborators of Reno Debets. A scholar is included among the top collaborators of Reno Debets based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reno Debets. Reno Debets is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ultrasonic Aspiration-Acquired Glioblastoma Tissue Preserves Lymphocyte Phenotype and Viability, Supporting Its Use for Immunological Studies 2025 ·Cancers ·(unknown), Zineb Belcaid, Rutger K. Balvers, (unknown), (unknown), (unknown), (unknown), Thierry van den Bosch, Jacques J. M. van Dongen, Reno Debets, Cristina Teodósio, Clemens M.F. Dirven, Martine L.M. Lamfers	0
2	T cell immunity in glioma and potential implications for immunotherapy: A systematic review 2025 ·Neuro-Oncology ·(unknown), Pim J. French, (unknown), (unknown), Levi van Hijfte, (unknown), Martin J. van den Bent, Reno Debets, Marjolein Geurts	0
3	Lipid-based nanosystems: the next generation of cancer immune therapy 2024 ·Journal of Hematology & Oncology ·(unknown), (unknown), (unknown), Mohamadreza Amin, Vito D’Agostino, Mojtaba Falahati, Sara Zalba, Reno Debets, Marı́a J. Garrido, (unknown), Ann L.B. Seynhaeve, Hayri E. Balcıoğlu, Timo L.M. ten Hagen	31
4	HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial 2023 ·BMC Cancer ·Joris B.W. Elbers, (unknown), Reno Debets, Stijn Keereweer, Esther van Meerten, Jaap Zindler, Yvette van Norden, Mischa S. Hoogeman, Gerda M. Verduijn, Michiel Kroesen, Remi A. Nout	4
5	Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries—Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients 2023 ·Cancers ·Willem de Koning, (unknown), (unknown), (unknown), (unknown), Reno Debets, Casper H.J. van Eijck, Dana A. M. Mustafa	1
6	Suitability of tumor-associated antibodies as predictive biomarker for response to immune checkpoint inhibitors in patients with melanoma: a short report 2023 ·Journal for ImmunoTherapy of Cancer ·Karlijn de Joode, Sharon Veenbergen, (unknown), (unknown), Reno Debets, Ron H.J. Mathijssen, Arjen Joosse, Marco W.J. Schreurs, Astrid A.M. van der Veldt	4
7	Intratumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients 2022 ·Cancers ·(unknown), Rebecca Wijers, (unknown), Senada Koljenović, Stefan Sleijfer, Robert J. Baatenburg de Jong, José A. Hardillo, Reno Debets, Hayri E. Balcıoğlu	6
8	Rintatolimod (Ampligen®) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program 2022 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Yarne Klaver, (unknown), Dana A. M. Mustafa, Reno Debets, Casper H.J. van Eijck	10
9	Detection of Low-Frequency Epitope-Specific T Cells in Blood of Healthy Individuals according to an Optimized In Vitro Amplification System 2022 ·The Journal of Immunology ·(unknown), (unknown), Reno Debets, Dora Hammerl	0
10	Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy 2021 ·Cancers ·(unknown), Mark W. H. Hoorens, Simone U. Dalm, (unknown), Reno Debets, Yann Seimbille, Marion de Jong	46
11	Transcriptomic Properties of HER2+ Ductal Carcinoma In Situ of the Breast Associate with Absence of Immune Cells 2021 ·Biology ·(unknown), Marcel Smid, Ronald van Marion, Dora Hammerl, Thierry van den Bosch, Mieke Timmermans, (unknown), Pieter J. Westenend, Reno Debets, John W.M. Martens, Carolien H. M. van Deurzen	0
12	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy 2021 ·Cancers ·Mirjam de With, Daan P. Hurkmans, Esther Oomen‐de Hoop, (unknown), Sander Bins, Samira El Bouazzaoui, Mandy van Brakel, Reno Debets, Joachim G.J.V. Aerts, Ron H. N. van Schaik, Ron H.J. Mathijssen, Astrid A.M. van der Veldt	9
13	V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma 2021 ·Cancers ·Pim Mutsaers, Hayri E. Balcıoğlu, Rowan Kuiper, Dora Hammerl, Rebecca Wijers, Mark van Duin, Bronno van der Holt, Annemiek Broijl, Walter A. Gregory, Sonja Zweegman, Pieter Sonneveld, Reno Debets	12
14	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors 2021 ·Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans, (unknown), Karlijn de Joode, (unknown), Edwin A. Basak, Annemarie Wijkhuijs, Markus Joerger, Reno Debets, Birgit C. P. Koch, Cor H. van der Leest, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen	15
15	Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes 2019 ·Clinical Cancer Research ·Dora Hammerl, Maarten P.G. Massink, Marcel Smid, Carolien H. M. van Deurzen, Hanne Meijers‐Heijboer, Quinten Waisfisz, Reno Debets, John W.M. Martens	37
16	<p>Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response</p> 2019 ·International Journal of Nanomedicine ·(unknown), Sara Zalba, Ann L.B. Seynhaeve, Reno Debets, Timo L.M. ten Hagen	31
17	Epithelial–Mesenchymal Transition in Human Prostate Cancer Demonstrates Enhanced Immune Evasion Marked by IDO1 Expression 2018 ·Cancer Research ·(unknown), Esther I. Verhoef, Marcel Smid, René Böttcher, Guido Jenster, Reno Debets, Geert J.L.H. van Leenders	43
18	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors 2016 ·Cancer Research ·Teresa Manzo, (unknown), Veronica Basso, (unknown), Rodrigo Hess Michelini, Michela Riba, Massimo Freschi, Angela Rita Elia, Matteo Grioni, Flavio Curnis, Maria Pia Protti, Ton N. Schumacher, Reno Debets, Melody A. Swartz, Angelo Corti, Matteo Bellone, Anna Mondino	21
19	TCR-engineered T cells to treat tumors: Seeing but not touching? 2016 ·Seminars in Immunology ·Reno Debets, Emmanuel Donnadieu, Salem Chouaı̈b, George Coukos	57
20	Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors 2009 ·Cancer Research ·Sara Bobisse, Maria Rondina, Anna Merlo, Veronica Tisato, Susanna Mandruzzato, Mario Amendola, Luigi Naldini, Ralph A. Willemsen, Reno Debets, Paola Zanovello, Antonio Rosato	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact